AACR 2022: Evaluating In Vivo Efficacy of Peptide Vaccines in Humanized B-HLA-A2.1 Mice

AACR 2022: Evaluating In Vivo Efficacy of Peptide Vaccines in Humanized B-HLA-A2.1 Mice

Conclusions

  • Human B2M and HLA-A2.1 proteins were detected in homozygous humanized B-HLA-A2.1 mice, while mouse B2M and H-2Kb/H-2Db proteins were not detected.
  • Introduction of hB2M-HLA-A2.1-H-2D in place of mouse B2M may affect the development of CD4+ and CD8+ T cells, which in turn affects the proportion of T cell subtypes in spleens of humanized mice.
  • HLA-A2.1–restricted CTL responses from vaccines were successfully detected in B-HLA-A2.1 mice. These results show that B-HLA-2.1 mice provide a powerful preclinical mouse model for in vivo evaluation of peptide vaccines.

Share:

    Please fill out the form below to request a download of this poster

    [posterfiledownload]